search
Back to results

NexGen TM Tibia Clinical Outcomes Study

Primary Purpose

Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
NexGen TM Monoblock Tibia
NexGen TM Modular Tibia
Sponsored by
Zimmer Biomet
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patient is at least 18 years of age.
  2. Patient qualifies for a primary cementless tibia total knee arthroplasty based on physical exam and medical history, including diagnosis of severe knee pain and disability due to at least one of the following:

    1. Rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis.
    2. Collagen disorders and/or avascular necrosis of the femoral condyle.
    3. Post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy.
    4. Moderate valgus, varus, or flexion deformities.
    5. The salvage of previously failed surgical attempts that did not include partial or total knee arthroplasty of the ipsilateral knee.
  3. Patient has participated in the study-related Informed Consent process.
  4. Patient is willing and able to provide written Informed Consent by signing and dating the IRB approved Informed Consent Form.
  5. Patient is willing and able to complete scheduled study procedures and follow-up evaluations as described in the Informed Consent Form.
  6. Independent of study participation, patient is a candidate for commercially available cementless NexGen TM tibial knee component, implanted in accordance with product labeling.

Exclusion Criteria:

  1. Previous history of infection in the affected joint.
  2. Active local or systemic infection that may affect the prosthetic joint.
  3. Insufficient bone stock on femoral or tibial surfaces.
  4. Skeletal immaturity.
  5. Neuropathic arthropathy.
  6. Osteoporosis or any loss of musculature or neuromuscular disease that compromises the affected limb.
  7. A stable, painless arthrodesis in a satisfactory functional position.
  8. Severe instability secondary to the absence of collateral ligament integrity.
  9. Rheumatoid arthritis accompanied by an ulcer of the skin or a history of recurrent breakdown of the skin.
  10. Patient has previously received partial or total knee arthroplasty for the ipsilateral knee.
  11. Patient is currently participating in any other surgical intervention studies or pain management studies.
  12. Patient is known to be pregnant or considered a member of a protected population (e.g., prisoner, mentally incompetent, etc.).
  13. Patient has a known or suspected sensitivity or allergy to one or more of the implant materials.

Sites / Locations

  • LA BioMed at Harbor-UCLA Medical Center
  • Cornerstone Orthopaedics & Sports Medicine, P.C.
  • Franciscan Health
  • Henry County Orthopedics and Sports Medicine
  • Woods Mill Orthopedics, Ltd
  • Pinehurst Surgical Clinic
  • University of Pennsylvania

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Monoblock

Modular

Arm Description

Subjects that receive the NexGen TM Monoblock Tibia

Subjects that receive the NexGen TM Modular Tibia

Outcomes

Primary Outcome Measures

Radiographic Parameters
Radiograph assessments

Secondary Outcome Measures

Oxford Knee Score
The Oxford Knee Score assesses function and pain after total knee arthroplasty.
Revision Rate
Rate of the number of revisions for any reason

Full Information

First Posted
August 31, 2017
Last Updated
September 22, 2023
Sponsor
Zimmer Biomet
search

1. Study Identification

Unique Protocol Identification Number
NCT03272373
Brief Title
NexGen TM Tibia Clinical Outcomes Study
Official Title
NexGen® TM Tibia Clinical Outcomes Study: Prospective Multicenter Study of the NexGen® TM Monoblock and Modular Tibias
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
October 3, 2017 (Actual)
Primary Completion Date
March 30, 2023 (Actual)
Study Completion Date
March 31, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zimmer Biomet

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this study is to evaluate clinical performance for the commercially available NexGen TM Monoblock Tibia and NexGen TM Modular Tibia used in primary cementless tibia total knee arthroplasty.
Detailed Description
This is a prospective, multicenter, non-randomized clinical study designed to facilitate the collection and evaluation of radiographic parameters, pain and function, survival of the device, and adverse event data. This clinical study will include the NexGen TM Monoblock Tibia and NexGen TM Modular Tibia as 2 single-arms being analyzed separately. The study will require each site to obtain IRB approval prior to study enrollment. All potential study subjects will be required to participate in the Informed Consent Process. All study subjects will undergo preoperative clinical evaluations prior to their cementless tibia total knee arthroplasty. An immediate postoperative radiograph will be required. Postoperative clinical follow-up and radiographic evaluations will be conducted at 6 weeks, 6 months, 1 year, and 2 years. The primary endpoint of this study is to evaluate the clinical performance of the implant at 2 years postoperatively using radiographic parameters. Radiographs will be assessed for the absence of progressive tibial radiolucencies, as defined in the radiographic protocol. The secondary endpoints of this study will evaluate the clinical performance of the implant at 2 years postoperatively, based upon: No revisions for any reason Oxford Knee Score >38

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Collagen Disorders and/or Avascular Necrosis of the Femoral Condyle, Post-traumatic Loss of Joint Configuration, Moderate Valgus, Varus, or Flexion Deformities

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
2 single arms being analyzed separately
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
182 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Monoblock
Arm Type
Other
Arm Description
Subjects that receive the NexGen TM Monoblock Tibia
Arm Title
Modular
Arm Type
Other
Arm Description
Subjects that receive the NexGen TM Modular Tibia
Intervention Type
Device
Intervention Name(s)
NexGen TM Monoblock Tibia
Intervention Description
Primary cementless tibia total knee arthroplasty
Intervention Type
Device
Intervention Name(s)
NexGen TM Modular Tibia
Intervention Description
Primary cementless tibia total knee arthroplasty
Primary Outcome Measure Information:
Title
Radiographic Parameters
Description
Radiograph assessments
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Oxford Knee Score
Description
The Oxford Knee Score assesses function and pain after total knee arthroplasty.
Time Frame
2 years
Title
Revision Rate
Description
Rate of the number of revisions for any reason
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient is at least 18 years of age. Patient qualifies for a primary cementless tibia total knee arthroplasty based on physical exam and medical history, including diagnosis of severe knee pain and disability due to at least one of the following: Rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis. Collagen disorders and/or avascular necrosis of the femoral condyle. Post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy. Moderate valgus, varus, or flexion deformities. The salvage of previously failed surgical attempts that did not include partial or total knee arthroplasty of the ipsilateral knee. Patient has participated in the study-related Informed Consent process. Patient is willing and able to provide written Informed Consent by signing and dating the IRB approved Informed Consent Form. Patient is willing and able to complete scheduled study procedures and follow-up evaluations as described in the Informed Consent Form. Independent of study participation, patient is a candidate for commercially available cementless NexGen TM tibial knee component, implanted in accordance with product labeling. Exclusion Criteria: Previous history of infection in the affected joint. Active local or systemic infection that may affect the prosthetic joint. Insufficient bone stock on femoral or tibial surfaces. Skeletal immaturity. Neuropathic arthropathy. Osteoporosis or any loss of musculature or neuromuscular disease that compromises the affected limb. A stable, painless arthrodesis in a satisfactory functional position. Severe instability secondary to the absence of collateral ligament integrity. Rheumatoid arthritis accompanied by an ulcer of the skin or a history of recurrent breakdown of the skin. Patient has previously received partial or total knee arthroplasty for the ipsilateral knee. Patient is currently participating in any other surgical intervention studies or pain management studies. Patient is known to be pregnant or considered a member of a protected population (e.g., prisoner, mentally incompetent, etc.). Patient has a known or suspected sensitivity or allergy to one or more of the implant materials.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kacy Arnold, RN, MBA
Organizational Affiliation
Zimmer Biomet
Official's Role
Study Director
Facility Information:
Facility Name
LA BioMed at Harbor-UCLA Medical Center
City
Torrance
State/Province
California
ZIP/Postal Code
90502
Country
United States
Facility Name
Cornerstone Orthopaedics & Sports Medicine, P.C.
City
Wheat Ridge
State/Province
Colorado
ZIP/Postal Code
80033
Country
United States
Facility Name
Franciscan Health
City
Mooresville
State/Province
Indiana
ZIP/Postal Code
46158
Country
United States
Facility Name
Henry County Orthopedics and Sports Medicine
City
New Castle
State/Province
Indiana
ZIP/Postal Code
47362
Country
United States
Facility Name
Woods Mill Orthopedics, Ltd
City
Chesterfield
State/Province
Missouri
ZIP/Postal Code
63017
Country
United States
Facility Name
Pinehurst Surgical Clinic
City
Pinehurst
State/Province
North Carolina
ZIP/Postal Code
28374
Country
United States
Facility Name
University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

NexGen TM Tibia Clinical Outcomes Study

We'll reach out to this number within 24 hrs